Literature DB >> 9495675

Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Fluconazole Global Susceptibility Study Group.

J Bille1, M P Glauser.   

Abstract

A fluconazole 25 microg disk diffusion test was used to test 2230 consecutively isolated Candida strains from 42 different hospital laboratories in 23 countries. Ninety seven percent of 1634 Candida albicans isolates and 83.4% of 596 non-Candida albicans isolates were susceptible to fluconazole, applying the proposed breakpoints (> or = 26 mm for susceptible strains and 18-25 mm for dose-dependent susceptible strains). This is the first hospital laboratory study to evaluate a large number and wide range of sequential Candida isolates from patients with all types of hospital infections. The fluconazole disk diffusion test appears to be a low-cost, reproducible, and accurate means of assessing the in vitro susceptibility of Candida isolates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9495675     DOI: 10.1007/BF01700561

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

Review 1.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 2.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

3.  Evaluation of a broth microdilution antifungal susceptibility test with a pH indicator: comparison with the broth macrodilution procedures.

Authors:  C Fournier; A Gaspar; F Boillot; J Villard
Journal:  J Antimicrob Chemother       Date:  1995-03       Impact factor: 5.790

4.  Fluconazole treatment of candidal infections caused by non-albicans Candida species.

Authors:  J W van 't Wout
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

5.  Fluconazole disk diffusion procedure for determining susceptibility of Candida species.

Authors:  A L Barry; S D Brown
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

6.  Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients.

Authors:  N Troillet; C Durussel; J Bille; M P Glauser; J P Chave
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

7.  Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria.

Authors:  J L Rodriguez-Tudela; J V Martinez-Suárez
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

8.  Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.

Authors:  J H Rex; M A Pfaller; A L Barry; P W Nelson; C D Webb
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans.

Authors:  A Espinel-Ingroff; J L Rodríguez-Tudela; J V Martínez-Suárez
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

10.  Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole.

Authors:  A L Colombo; F Barchiesi; D A McGough; A W Fothergill; M G Rinaldi
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

View more
  6 in total

1.  Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods.

Authors:  E Cantón; J Pemán; A Carrillo-Muñoz; A Orero; P Ubeda; A Viudes; M Gobernado
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.

Authors:  G Kronvall; I Karlsson
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 3.  Invasive candidiasis in pediatric intensive care units.

Authors:  Sunit Singhi; Akash Deep
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

4.  Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.

Authors:  Kevin C Hazen; Ellen Jo Baron; Arnaldo Lopes Colombo; Corrado Girmenia; Aurora Sanchez-Sousa; Amalia del Palacio; Catalina de Bedout; David L Gibbs
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

5.  Comparison of results obtained by testing with three different agar media and by the NCCLS M27-A method for in vitro testing of fluconazole against Candida spp.

Authors:  M Carmen Rubio; Joaquina Gil; Inmaculada Ramírez De Ocáriz; Rafael Benito; Antonio Rezusta
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

6.  Species diversity of yeast in oral colonization of insulin-treated diabetes mellitus patients.

Authors:  Regina Helena Pires Gonçalves; Elaine Toscano Miranda; José Eduardo Zaia; Maria José Soares Mendes Giannini
Journal:  Mycopathologia       Date:  2006-08       Impact factor: 3.785

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.